EnsoData, Nonin Partner to Offer Affordable Home Sleep Testing

MADISON, Wisconsin—EnsoData, a provider of health care artificial intelligence (AI), and Nonin, a provider of pulse oximetry devices, announced a partnership to address the underserved and undiagnosed sleep apnea patient population with a collaborative home sleep apnea testing approach. The partnership will combine the recently FDA-cleared EnsoSleep PPG software as a medical device (SaMD) algorithm with Nonin’s WristOx2 Model 3150 reusable wrist-worn device, offering sleep labs an affordable solution to test for sleep apnea at home. 

Obstructive sleep apnea (OSA) is an increasingly common condition that if left untreated, exacerbates many other cardiac, respiratory, metabolic, neurodegenerative and mental health problems. It affects almost 1 billion people globally, including 425 million who have moderate to severe OSA. Severe OSA is characterized by 30 or more apnea events per hour—which manifests in a cycle where patients stop breathing, on average, once every other minute. The companies said this partnership aims to address this patient population by delivering a collaborative solution to help improve overall population health metrics.

Nonin said its WristOx2 Model 3150 devices deliver fast, accurate oxygen saturation and pulse rate readings in challenging conditions, including low perfusion and in motion by using sensors that provide continuous SpO2 monitoring and data recording.

“Customers who choose Nonin, choose durability, accuracy and equity,” said John Hastings, CEO of Nonin Medical. “Combining our class-leading noninvasive monitoring products with EnsoData’s innovative AI platform will increase patient access to quality diagnosis in the significantly under-served field of sleep apnea.” 

EnsoSleep PPG is interoperable with compatible FDA-cleared pulse oximetry devices, which now includes the Nonin WristOx2 Model 3150, allowing the AI to analyze collected data and provide sleep staging and event detection analysis to sleep labs and clinicians using Nonin devices. 

“This partnership is an important step toward increasing patient access to quality sleep care,” said Justin Mortara, CEO of EnsoData. “As a trusted manufacturer of high-quality pulse oximetry solutions, Nonin’s devices provide more innovative hardware options for our customers to use in conjunction with EnsoSleep PPG. We are excited to launch this collaboration and continue to grow the EnsoData network of sleep medicine partnerships.”